Hefei Industrial Pharmaceutical Institute Co., Ltd

Hefei Amvite Pharmaceutical Co., Ltd

China Pharmaceutical University

Zhaoxing Chu

Guangwei He

Jiajia Mo

Qinlong Xu

Yan Zhao

Yi Yang

Junwei Wang

Hui Li

Yungen Xu

Lincui Bian

Weizhong Liu

Yuanfeng Gu

Li Shao

Qihua Zhu

Feng Li

The present disclosure relates to the field of pharmaceutical chemistry, in particular to a class of PARP/PI3K double-target inhibitors (I) containing structures of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine and phthalazin-1(2H)-one and a preparation method thereof. As proved by pharmacodynamic tests, the compounds of the present disclosure have PARP/PI3K double-target inhibitory activity and can be used for anti-tumor.

PARP/PI3K double-target inhibit containing pyridopyrimidine structure

The disclosure relates to the field of pharmaceutical technology, in particular, to a compound pharmaceutical composition for treating skin inflammatory diseases, which is characterized in that an active ingredient of the compound pharmaceutical of the disclosure is composed of tofacitinib and crisaborole, and the composition has a stronger therapeutic effect and a lower dosage with a significant synergistic therapeutic effect. The pharmaceutical composition of the disclosure can be used to treat skin inflammatory diseases.

Compound pharmaceutical composition for treating skin inflammatory diseases

The disclosure relates to the field of medicinal chemistry, in particular, to a class of small molecule compounds for inhibiting phosphodiesterase 4 (I), a preparation method thereof and a pharmaceutical composition comprising the compound. The pharmacodynamic test proves that the compound of the disclosure has the inhibitory activity of PDE-4 enzyme and the efficacy of inflammation treatment. 

Compound having effects of inhibiting phosphodiesterase 4, preparation method thereof and pharmaceutical use thereof

Growing community of inventors

Anhui, China

Zhaoxing Chu